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Abstract
Background: New treatment approaches for psychosis indicate that effective interventions require a therapeutic focus 
on emotional regulation, cognitive appraisals, and functioning. Efficacy of psychotherapeutic interventions’ evaluation 
has changed from exclusively assessing symptom frequency/severity to a comprehensive and functional assessment 
of interference, functioning, and the relationship people have with symptoms. This shift led to new needs in clinical as-
sessment. This study aimed to develop and submit to expert evaluation a new clinical interview for psychotic disorders 
which considers the new needs of the field.
Methods: CIPD was developed by a multidisciplinary team considering the DSM-5 criteria for psychotic and affective 
disorders. Relevant information was retrieved from leading research in the area of assessment and evaluation of inter-
ventions in psychosis. An expert panel of recognized professionals in the main areas of mental health evaluated each 
question of the interview (5-point Likert scale) regarding pertinence and clarity.
Results: A detailed description of CIPD is presented. Results from the experts’ evaluation showed that, overall, the CIPD 
questions were evaluated as pertinent and clear for the target population. 
Conclusion: CIPD assesses both diagnosis or presence of psychotic symptoms and symptoms’ psychosocial cor-
relates. Psychotherapy and pharmacotherapy may benefit from CIPD since it may detect subtle changes caused by 
intervention and changes in areas other than symptom reduction.
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Background
Psychotic disorders are defined in the DSM-5 [1] as en-
compassing five specific domains of psychopathology: 
hallucinations, delusions, disorganized thought (speech), 
disorganized or abnormal motor behavior (including cata-
tonia), and negative symptoms. The term 'psychotic disor-
der' as a clinical entity can be used as a generic diagnostic 
term since it covers a set of severe conditions usually asso-
ciated with high levels of adjustment difficulties, suffering, 
and poor clinical (psychopathological and physical) and 
social outcomes [2]. Nevertheless, several longitudinal and 
long-term studies have showed rates of approximately 50% 
for significant improvement and relative independence in 
functioning outcomes, as well as rates of approximately 
25% for full recovery (for a review see [3]) in severely 
mentally ill patients.
Clinical assessment in psychosis
There are several assessment instruments for assessment 
of the psychosis spectrum: both in clinician-rated form 
and patient self-report form. The most widely used cli-
nician-rated instruments including assessment of psy-
chotic symptoms are: a) the Brief Psychiatric Rating Scale 
(BPRS [4]), a scale designed to measure several psychiat-
ric symptoms along a 1-7 scale, including mood, behav-
ioral, and psychotic symptoms among others; and b) the 
Positive and Negative Symptoms Scale (PANSS [5]), a 
scale designed specifically to assess severity of psychotic 
symptoms also in a 1-7 rating scale, encompassing scales 
of positive and negative symptoms and general psychopa-
thology. Recently, the Signs and Symptoms of Psychotic 
Illness (SSPI[6]) – a 20 item scale assessing 6 major psy-
chopathological processes, common in psychosis – was 
developed with the aim of  overcoming limitations of the 
two previously described instruments. 
Research context-specific interviews and symp-
tom-based instruments such as the following examples 
have also been developed and are widely used: a) Di-
agnostic: the Diagnostic Interview for Genetic Studies 
(DIGS [7]), Diagnostic Interview for Psychoses (DIP 
[8]), or the Psychiatric Interview for Genetic Studies 
(EP-GENE [9]); b) Symptom-specific: the Clinical As-
sessment Interview for Negative Symptoms (CAINS 
[10]); Psychotic Symptom Rating Scale (PSYRATS [11]) 
for hallucinations and delusions.
Interviews for genetic studies may be of particular util-
ity in terms of epidemiological and genetic research and 
for initial assessment of diagnosis in clinical practice rather 
than for a comprehensive assessment of symptom severity 
or change. They are often extensive and particularly diag-
nosis and phenomenology-oriented. On the other hand, al-
though symptom-specific instruments are often more prac-
tical for clinical contexts and very comprehensive in terms 
of symptom severity, the diagnosis-valence is not always 
present or sufficiently addressed (e.g. PANSS).
 The Recovery model and assessment challenges
Notwithstanding the tradition of looking at psychotic 
disorders as exclusively biological conditions requiring 
mostly treatment within a biological framework, research 
stressed out the benefits of a bio-psycho-social approach 
with psychosocial interventions playing a major role in 
coping with symptoms, reducing the disease’s burden, and 
enhancing patients lives. Particularly interventions based 
on the theory of learned behavior and cognitive mediation 
—mainly cognitive-behavioral therapy—have been shown 
as effective for this population [2, 13-15].
The recovery model in mental health has been receiv-
ing growing attention in the field of psychotic disorders, 
mainly in schizophrenia. Although still an evolving and 
rather controversial concept, recovery has been defined as 
a complex and multidimensional process that can be char-
acterized under two different approaches: objective as-
pects of recovery (recovery as an outcome) and subjective 
aspects of recovery (recovery as a process). Recovery as an 
outcome is based on whether certain operationally defined 
criteria in certain domains (usually regarding psychopa-
thology and functioning) are met, and recovery as a pro-
cess is more related to the subjective process of changing 
and embracing a meaningful life [16] (with several guid-
ing principles being highlighted, such as self-directedness, 
empowerment, and hope among others [17]), this being 
independent of the person’s clinical improvement [18]. 
These different definition approaches were also shown to 
be dependent on who is defining recovery. For example, 
researchers defining it more in terms of outcome criteria 
versus patients or family members defining recovery as an 
ongoing change process [19]. Studies did not reveal an as-
sociation between symptom severity (objective recovery) 
and subjective self-report of being in recovery [18]. The 
‘recovery journey’ has been associated with several char-
acteristics, such as being an active, unique, multidimen-
sional, and non-linear process, evolving through stages, 
encompassing different processes, namely connectedness 
(with others/community), hope and optimism about the 
future, identity, meaning in life, and empowerment [20].
Research informing clinical practice has been suggest-
ing recovery-informed interventions where the therapeu-
tic tools and techniques should support recovery processes 
[20]. Therefore, interventions should be strengths-based 
and promote a richer and more positive self-experience 
across several dimensions. Psychotherapeutic interventions 
have been shifting from a symptom-focused approach to a 
more person-based approach, highlighting the importance 
of valued living directions, relationship with thoughts and 
emotions, acceptance and willingness towards experiences 
and non-judgmental attention (e.g. [21,22]).
In order to provide evidence-based interventions—as 
recommended in international guidelines [23]—and con-
sidering the different targets proposed by the new models 
of intervention in psychosis, this paradigm shift in inter-
vention should be accompanied by changes in assessment.
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Integrated assessment of Psychosis: Assessment tools 
derived from the Recovery Model
This shift to an approach more focused on a growth, self-de-
velopment, empowering process led to new advances in 
the assessment of psychosis. Several instruments measur-
ing personal recovery from psychosis have been prolifer-
ating in the past years. Some commonly used instruments 
are the Recovery Assessment Scale [24] (41 items assessing 
mainly hope and self-determination), the Mental Health 
Recovery Measure [25] (a 30-item scale measuring con-
structs as self-empowerment, self-redefinition, function-
ing, well-being, among others), the Self-Identified Stage of 
Recovery [26] (a brief measure aiming to assess the stage 
of recovery of the consumer, from one’s own perspective), 
the Illness Management and Recovery Scales [27] (mea-
sure with client and clinician versions measuring aspects of 
illness management and recovery),  among others.
With the intention of summarizing and critically an-
alyzing data for the existing measures, several compre-
hensive and integrative systematic reviews on existing 
and psychometrically tested self-report measures specifi-
cally developed for severe mental illness, mainly psychot-
ic disorders emerged [28-30]. The Recovery Assessment 
Scale has been suggested as the best available measure (e.g. 
[28,29]). Interestingly, along with the evolution of assess-
ment measures for personal recovery, the recovery orien-
tation of mental health services has also been of major in-
terest in research, with several measures being developed 
(for a review see [31]).
Despite the growing body of research in assessment 
tools within the Recovery Model, symptom assessment 
tools and diagnostic interviews seem to be somewhat aside 
of this movement, and clinicians and researchers usually 
have to combine several assessment instruments in order 
to perform an integrative assessment. Furthermore, even 
considering symptom assessment, it is important to un-
derstand the relationship people have with symptoms (e.g. 
conviction, perceived interference, and empowerment) in 
addition to frequency, severity, and duration, since such 
an assessment provides clinicians with intervention tar-
gets that have been associated with improvement (e.g. less 
symptom believability associated with lower rates of re-
hospitalization [32]).
Therefore, the present study had two major objectives. 
First, we aimed at developing a user-friendly, clinically 
relevant, comprehensive, and practical clinical interview 
that could be used both in research and clinical settings. 
We intended to provide researchers and clinicians with an 
assessment tool developed for assessing both diagnosis or 
presence/absence of psychotic symptoms, the psychosocial 
correlates of the symptoms (such as the relationship with 
symptoms, empowerment or interference caused by symp-
toms) and the most relevant co-morbidities (and their pos-
sible relationship with psychotic symptoms). Therefore, we 
intended to develop a clinical interview that allows a com-
prehensive assessment of symptom change (evaluation of 
clinical interventions). Moreover, to our knowledge there 
are still no interviews based on DSM-5 criteria specifically 
developed for psychotic-spectrum disorders.
The second goal was to submit the developed interview 
to the quantitative and qualitative evaluation of an expert 
panel in order to preliminarily assess content validity.
Methods
CIPD rationale and development
The CIPD was developed by a multidisciplinary team that 
comprised professionals from Psychiatry or Psychology 
backgrounds with experience in both: a) assessment and 
clinical intervention; and b) development and validation 
of assessment tools, including diagnostic interviews (for 
severe mental illness and other psychiatric populations).
With the DSM-5 release, the psychotic-spectrum diag-
nostic assessment is in need for updated assessment tools, 
particularly clinical interviews. Thus, the CIPD was devel-
oped based upon the DSM-5 criteria for psychotic disor-
ders, mood-related disorders, and to a lower extent sub-
stance-use related disorders, social anxiety disorder, and 
trauma-related disorders (the main focus being on the psy-
chotic symptoms). The in-depth and critical analysis of the 
DSM-5 criteria constituted the basis for the development 
of the diagnostic valence of the interview. Additionally, in-
ternational guidelines were consulted in order to refine the 
assessment of specific symptoms (e.g. the ‘National Institute 
of Mental Health’s consensus conference on negative symp-
toms’ [33]). The additional phenomenological assessment 
questions were derived from literature review and discus-
sion between clinical psychologists and psychiatrists with 
expertise in psychotic disorders and severe mental illness.
One of the main strengths of the CIPD, in comparison 
with interviews designed exclusively for a diagnostic pur-
pose, is that it also includes several additional questions 
and ratings not needed or intended for diagnostic purpos-
es. This clinical valence of the CIPD aims at evaluating the 
psychosocial correlates of the symptoms and, therefore, at 
being useful throughout the therapeutic process (identify-
ing targets for intervention, assessing change, evaluating 
the efficacy of interventions). These questions and ratings 
were also derived from literature review and discussion of 
clinical practice. Several existent diagnostic and symptom 
assessment interviews (psychotic-spectrum and other dis-
orders) were also analyzed and discussed for strengths and 
limitations.
The development of the optional section (assessing so-
cial anxiety and trauma) was motivated by recent research 
emphasizing social anxiety symptoms and post-traumatic 
symptoms to the psychotic experience. The co-morbidity 
of psychotic-spectrum disorders and social anxiety disorder 
is widely known (e.g. [34]). On the other hand, the experi-
ence of a psychosis diagnosis and psychotic symptoms has 
been considered as a challenging or traumatic life event (e.g. 
Clinical Interview for Psychotic Disorders4
ARC Publishing
pertinent/completely clear) scale. All questions of the in-
terview were intended to be rated and a rating form was 
distributed with the interview. Participants were instruct-
ed to write suggestions, comments and critiques whenever 
they felt appropriate. For all questions with a score (either 
on pertinence or clarity) below 3 the participants were 
asked to correct or suggest modifications to the question.
Results
CIPD basic format
The CIPD is a new semi-structured clinical interview, 
based on DSM-5 criteria, for the assessment of the psy-
chotic-spectrum. 
In order to better meet the objectives of the clinician/
researcher, the CIPD can be used with different timeframe 
periods. At the beginning of the interview, the clinician/
researcher must choose the time period that best suits the 
assessment goals (e.g. lifetime for diagnosis; last week for 
monitoring change/evaluation of interventions) and fol-
low the instructions that help the participant to better un-
derstand the period of time to which all the interview will 
be referring to. An important note is that there are slight 
differences in assessment depending on the time period 
chosen. For example, if the assessment is focusing on the 
present moment (last week) some ratings should be made 
by clinical observation (e.g. disorganization, some negative 
symptoms), but when assessing under a lifetime perspec-
tive, questioning should be privileged.
The CIPD follows a clinical approach of interviewing 
where questions are grouped by diagnosis and criteria for a 
specific diagnosis. If the patient fails to meet certain crite-
ria, the interview provides “skip out” instructions directing 
the interviewer to the following criteria or diagnosis. The 
diagnosis sections tend to begin with an introduction to the 
section (what is going to be assessed) followed by one or 
two direct close-ended questions about specific symptoms 
(inviting a ‘Yes’ or ‘No’ response). If there is a positive an-
swer, the CIPD allows the clinician/researcher to gather 
comprehensive symptom information through a) requests 
for elaboration; or b) follow up questions (inviting more 
elaborate answers). It could be necessary for the interview-
er to ask more questions in order to understand the pres-
ence/severity/interference of the symptoms. Regarding 
specific symptoms (known to be of difficult assessment ei-
ther because of stigma/shame issues or lack of insight), ad-
ditional questions are already suggested as supplementary 
questions. On the other hand, if a symptom is clearly pres-
ent (e.g. delusions, negative symptoms) it should be scored 
accordingly even if the patient denies it. There are adapta-
tions in several questions for patients with poor insight (in 
sections where insight might be particularly compromised). 
This interview also has a clinical focus on the current 
psychosocial impact of symptoms. At the end of each psy-
chotic symptom section, the participant is asked to rate 
the interference associated with the symptom along a 0 
[35]) and several studies have associated the occurrence of 
psychotic symptoms with post-traumatic stress disorder 
(e.g. [36]). Therefore, this optional section aims at assessing 
symptoms that can be ameliorated with intervention. 
A main concern during the development process was 
the inclusion of the patients’ views and opinions regard-
ing their experience. The CIPD tries to promote an active 
participation by the patients instead of them being mere 
passive subjects of the clinical assessment. In our opinion, 
this is a major limitation of the existing interviews.
The CIPD evolved from multiple drafts. After agree-
ment from the development team, the CIPD was then sub-
mitted to an expert panel evaluation in order to assess: the 
relevance of the items and the clarity of language for the 
specific population (procedure below). All rating forms 
and observations were analyzed. Questions with overall 
low scores suffered major transformations or were elimi-
nated. Based on quantitative and qualitative data obtained, 
the sections with major modifications were the ‘Delusions’ 
subsection (question reformulation), ‘Negative symptoms’ 
subsection (question reformulation and additional ques-
tions were added for better assessment), the ‘Disorganized 
Behavior and Speech and Catatonia’ subsection (question 
reformulation, elimination of questions particularly re-
garding observable behavior). In all sections, assessment 
of interference, frequency, and severity were refined with 
additional questions and key instructions for the inter-
viewer. In order to obtain more reliable scores regarding 
negative symptoms, disorganization and motor symptoms, 
questions were also reformulated to include ratings based 
on clinical observation (‘Clinical observation items’ with 
specific instructions and recommendations) when the in-
terview aims to assess current symptoms in “the last week”.
Expert panel evaluation
Participants 
A group of 17 professionals with extensive experience in 
working with psychotic-spectrum disorders were invit-
ed to join an expert panel whose purpose was to critical-
ly evaluate the CIPD. We benefited from the evaluation 
of 6 psychiatrists, 5 clinical psychologists, 4 nurses (with 
specialization in Mental Health and Psychiatric Nursing) 
and 2 social workers (working in severe mental illness 
settings). The participants had in average 17 years of pro-
fessional experience in severe mental illness and psychotic 
disorders settings (5 to 32 years). Participants were part 
of community mental health teams specialized in psychotic 
disorders, worked in first psychotic episode services, dual 
disorder diagnosis units and/or in acute inpatients units.
Procedure
The experts were asked to carefully analyze and evaluate 
the interview in terms of two criteria: a) pertinence of the 
items and b) clarity of language (for the specific popula-
tion) along a 0 (not at all pertinent/clear) to 5 (extremely 
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(no interference) to 5 (extreme interference) scale. In the 
delusions section, the participant is also asked to rate the 
conviction associated with the belief (0 –  I currently do 
not believe this - to 5 – I currently am certain that this 
corresponds to reality – scale). At the end of each psychot-
ic symptom section (delusions, hallucinations, negative 
symptoms, disorganization and catatonia) the patients are 
also asked to place themselves in a continuum (with the aid 
of a visual analogue scale) regarding the perceived sense 
of empowerment towards symptoms (see Figure 1). In the 
substance use section the interviewer asks the participant 
about motivations for substance use, including motives 
linked to psychosis, along a 0 (I never use [substance] be-
cause of that) to 5 (I always use [substance] because of that) 
scale. At the end of each major section, participants are 
also asked to evaluate how the difficulties in the area just 
assessed have disturbed their lives (0-5 scale) in different 
areas (family, romantic relationship, work/school, social 
relationships, finances, and daily routine).
The clinician has to evaluate symptom severity, fre-
quency and interference along a 0 (Minimal severity, with-
out clinically relevant distress | Not present | No interfer-
ence at all) to 5 (Maximal Severity – it may represent danger 
to self or others | Occurs constantly | Major interference in 
all areas of life, seriously impaired functioning with diffi-
culties in activities of daily living) rating scale. All points 
of the interviewers’ scales are defined at the beginning of 
the interview. Figure 2 presents the summary table with 
instructions for clinician-rated measures and patient-rated 
scales that is provided for each psychotic symptom and that 
can be converted in quantitative scores. 
Sections of the CIPD
The CIPD comprises a brief open-ended questioning over-
view followed by three mandatory sections and one op-
tional section. The mandatory sections are only mandatory 
if the objective is to perform diagnosis. The CIPD can also 
be used to evaluate the efficacy of interventions and there-
fore clinicians/researchers can apply only the sections of 
interest (e.g. psychotic symptoms section to assess change 
in severity, conviction, interference, or empowerment re-
garding psychotic symptoms). The sections of the CIPD 
are described in detail below.
1 2 3 4 5
Less capable/Nothing I can 
do/No hope
Definitely capable/I have 
tried things/Certain of 
improvement
Component Guiding descriptions A B C D
Perceived ability to cope
I do not feel at all capable of dealing with it
I feel I am barely capable of dealing with it
I feel I am moderately capable of dealing with it
I feel I am quite capable of dealing with it
I feel I am definitely capable of dealing with it
Perceived control & Ideas 
to improve*
I feel that none of the aspects of these difficulties are at all dependent of 
me (there is nothing I can do. I have no ideas).
I feel that the aspects of these difficulties are not only dependent of me 
(there are few I can do. I have ideas but I do not think I could act on them).
I feel that some aspects of these difficulties are dependent of me (there is 
something I can do. I have ideas that I intend to try in the future)
I feel that some aspects of these difficulties are dependent of me (there 
are several things I can do. I have ideas that I intend to try soon)
I am certain that some aspects of these difficulties are dependent of me 
(there are several things I can do. I have already acted on my ideas)
Hope
I do not have any hope that improvement is possible.
I have little hope that improvement is possible.
I have some hope that improvement is possible.
I am quite hopeful that improvement is possible.
I am certain that improvement is possible.
Figure 1. Measuring empowerment regarding psychotic symptoms. A=Delusions; B=Hallucinations; C=Negative Symptoms; D=Disorganization 
and Catatonia; *The ideas to improve does not have to agree with mental health professionals’ therapeutic plans (e.g. taking medication, going to appoint-
ments), these are ideas the patient considers to be useful. 
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Item to 
assess
Clinician-rated (CR) / 
Participant-rated (PR)
Guiding questions and instructions*
Duration CR For how long did/do the [symptom] last? (days/weeks/months/years?)
Conviction PR (0-5 rating scale) How much do you think this idea [symptom] corresponds to reality? How much 
do you believe this to be true? 
Interference PR (0-5 rating scale) How much do you think this [symptom] interferes with your life? It may be 
necessary to explain what interference means (see questions of Interference 
CR) 
Interference CR (0-5 rating scale) How does [symptom] affect you emotionally? Does the [symptom] influence your 
everyday life? Your ability to work? What did you stop doing/became difficult 
to do because of [symptom]? Do you have new behaviors/actions because of 
[symptom]? Did [symptom] alter your relationship with others? How?
(+ previous questions + clinical observation)
Frequency CR (0-5 rating scale) Does this [symptom] appear every day/week/how often?
(+ previous questions + clinical observation)
Severity CR (0-5 rating scale) (previous questions + clinical observation)
Figure 2. Guiding questions for clinician and participant-rated scores. *All ratings (except for duration) refer to the current symptomatology. Cur-
rent symptomatology can be considered in a period of 1 and a half months (maximum) for participants without present symptoms. 
Introduction
The first moments of the interview are aimed at estab-
lishing a non-directive relationship with the patient. The 
interviewer is instructed to explain the functioning of the 
CIPD and provide all explanations about procedures. The 
time period that will be used must be clarified at this mo-
ment (following instructions provided). This overview 
ends with an open-ended question about possible prob-
lems/difficulties that the participant might have/had in 
the past. This section also includes a rating scale (assessed 
by the patients and their clinicians) regarding adherence to 
anti-psychotic medication.
Psychotic-spectrum disorders
The first section aims at a detailed assessment of psychot-
ic (positive and negative) symptoms and is divided into 
two sub-sections. In the ‘positive symptoms’ section, the 
CIPD comprises the assessment of delusions and halluci-
nations—with specific questioning for the most common 
delusion themes and hallucinations’ sensory modalities. It 
has also additional phenomenological assessment concern-
ing thought alienation. Disorganized speech, behavior, 
and catatonia are also targets of assessment. The ‘nega-
tive symptoms’ section includes assessment of blunted/
inappropriate affect, alogia, anhedonia, asociality, and 
avolition. This section also provides questions aimed at as-
sisting the differential diagnosis between negative and de-
pressive symptoms. In all subsections, there are questions 
that allow to specify whether symptoms occur(ed) during 
depression, mania, substance use, medical illness or in the 
absence of these conditions.
Mood-related disorders
The second section aims to evaluate major dysfunction-
al humor episodes (depressive, manic, and hypomanic). 
A guided differential diagnosis subsection with bereave-
ment is provided (following DSM-5 criteria) for use when 
appropriate. This section also allows a qualitative assess-
ment of self-concept and social comparison with others 
and assessment of suicide risk (current signals, past risk 
factors and present association between psychotic symp-
toms and suicidality).
Substance-related and addictive disorders
The third section provides questions aiming at  assessing 
the presence of alcohol and cannabinoid-related disorders 
and associated interference. These two substances were se-
lected because they are usually the most prevalent in com-
bination with a psychotic-spectrum disorder. Taking into 
consideration that some patients have poor insight, some 
questions are adapted to these cases. Optional questions 
about the motives that precede substance use are provided, 
including motivations related with psychotic symptoms (al-
leviation/elimination) and medication side effects.
Associated Symptoms [Optional] 
In this last optional section, the CIPD allows clinicians to 
assess the presence of social anxiety symptoms and trau-
ma related to the psychotic experience (that might include 
psychotic episodes, hospitalizations, and stigma). 
Appendices
At the end of the interview is provided a table illustrating 
the correspondence between the CIPD questions and the 
items required to score the Operational Criteria Checklist 
for Psychotic Illness (OPCRIT 4.0[37]).
Diagnosis included and diagnosis-independent ratings
The following diagnoses can be generated by the CIPD: 
1) Section 1: Psychotic-Spectrum disorders – Delusional 
Disorder [297.1 (F22)]; Brief Psychotic Disorder [298.8 
(F23)]; Schizophreniform Disorder [295.40 (F20.81)]; 
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Schizophrenia [295.90 (F20.9)]; Schizoaffective Disorder 
[295.70 (F25.0/1)]; 2) Section 2: Humor-related disorders 
– Major Depressive Disorder [296.xx (F32/33.xx)]; Bipolar 
I Disorder [296.xx (F31.xx)] e Bipolar II Disorder [296.89 
(F31.81)]; 3) Section 3: Substance-related and addictive 
disorders: Alcohol use disorder [305/3.xx (F10.xx)]; Can-
nabis use disorder [305/4.xx (F12.xx)]. In the optional sec-
tion (Section 4: Associated Symptoms) no diagnoses can 
be defined, nevertheless the clinician/researcher can de-
rive important information about social anxiety and trau-
ma associated with the psychotic experience. Throughout 
the interview, if there is evidence of other (primary or 
co-morbid) disorders  not covered by CIPD, other assess-
ment tools must be used.
Several diagnosis-independent ratings are available for 
each set of symptoms, such as severity, conviction, fre-
quency, interference in several areas of life, and empower-
ment. These ratings are performed both by the interview-
er and the participant. The interview also allows a ‘risk of 
suicide’ score and independent scores for several motives 
for substance use.
CIPD Output
The CIPD has a checklist at the end which helps the cli-
nician/researcher to organize the qualitative, categorical, 
and quantitative information gathered and establish diag-
nostic output and a differential diagnosis. The interview 
also provides several quantitative subscales for objective 
severity, frequency, and interference of psychotic, mood 
and substance use-related symptoms (clinician-rated—
through provided rating scales) and conviction (regard-
ing delusional activity) and perceived interference in 
several areas of life (all sections) (patient-rated). A total 
score of empowerment is also an output for psychotic 
symptoms. These scales can be combined in total scores 
for frequency of positive symptoms; severity of positive 
symptoms; severity of negative symptoms; interference 
of positive symptoms (interviewer rated and patient-rat-
ed); interference of negative symptoms (interviewer rat-
ed and patient-rated). It is also possible to compute a total 
score regarding the psychotic illness. A total score of in-
terference for each area is provided as well, since the pa-
tient is also instructed to assess subjective interference of 
the positive and negative symptoms in the various areas 
of life (family; work/school; social relationships; financ-
es; and daily routine), as well as a total score of empower-
ment with psychotic symptoms. In the mood section, the 
CIPD provides total scores for interference and severity 
of symptoms (clinician rated) and interference in several 
areas of life (patient rated). The same scores are available 
for the ‘substance use’ section with, additionally, indi-
vidual scores for each motive for substance use. A total 
score for suicide risk, as well as a total score for adher-
ence to anti-psychotic medication can also be computed. 
It is possible to score the OPCRIT 4.0 from the scores 
obtained in the CIPD.
Expert panel evaluation
The results from the expert panel evaluation are presented 
in Table 1. 
Discussion
Considering the paradigm shift in intervention and, conse-
quently, assessment of psychosis motivated by the recovery 
model, the present study aimed at developing a clinically 
relevant, comprehensive, and practical clinical interview. 
This interview intended to provide an assessment of diag-
nosis or presence/absence of psychotic symptoms, the psy-
chosocial correlates of the symptoms (such as the relation-
ship with symptoms or interference caused by symptoms) 
and co-morbidities. The developed interview—CIPD—was 
then submitted to an expert panel for evaluation.
The expert panel evaluation revealed high scores both 
in terms of the pertinence of questions for diagnosis, phe-
nomenology assessment, and psychosocial correlates of 
symptoms, as well as regarding language suitability for 
the psychosis population. This provides useful indicators 
of the possible acceptability of the CIPD by professionals 
working with psychosis populations and their perception 
of clinical utility. Nevertheless, this was solely a prelimi-
nary content validity evaluation and the CIPD is in need of 
further psychometric studies and evaluation of routine use.
Clinical relevance
A semi-structured clinical interview with the aim of as-
sessing both diagnosis or presence/absence of psychotic 
symptoms and the psychosocial correlates of the symptoms 
is an extremely useful tool for clinicians for a) assessing 
intervention targets; b) monitoring change; and c) evalu-
ating the efficacy of their psychotherapeutic interventions. 
After validation, the CIPD can also be useful in clinical re-
search as an outcome measure in all forms of therapeutic 
intervention in psychosis. 
In terms of practicality, the CIPD is not intended to be 
extensively time-consuming and the absence of detailed 
assessment of other (non-related to psychosis) psychiatric 
conditions/symptoms contributes to this end. In the over-
all process of developing the CIPD, we were concerned 
with suiting the interview for the severely mentally ill, 
taking into account this population’s special features such 
as cognitive and attention deficits, difficulties in abstract 
thinking, negative symptoms, poor rapport, poor mental-
ization and theory of mind skills, and difficulties in  inter-
personal relationships. This concern was aimed at reduc-
ing the patient’s and clinician’s burden in the diagnosis and 
assessment process (this advantage is also transposable to 
research settings where reducing the participant’s burden 
is even more advised). A clinical interview that allows both 
symptom and diagnostic assessment and subjective experi-
ence of symptoms and psychotic illness in a manner con-
gruent with the Recovery model for severe mental illness 
offers important advantages. The fact that two important 
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Table 1. Expert panel evaluation.
Clinical 
Psychologists
(n=5)
Psychiatrists
(n=6)
Nurses 
(Psychiatry)
(n=4)
Social Workers 
(Psychiatry)
(n=2)
Highest 
possible score Mean (SD) Mean (SD) Mean (SD) Mean (SD)
 (*)
Professional experience in mental 
health (years) - 16.60 (7.06) 18.50 (9.01) 23.25 (8.62) 5.50 (0.71)
Psychotic Symptoms (Total) 215
Pertinence 117.70 (3.14) 118.95 (1.60) 120.32 (0.75) -- 
Clarity 113.41 (5.77) 114.17 (4.39) 119.03 (1.15) 116.70 (2.83)
Psychotic Symptoms (Positive 
Symptoms - Total) 175
Pertinence 166.54 (3.91) 167.31 (2.99) 169.39 (1.50) --
Clarity 160.93 (7.52) 161.14 (5.44) 166.81 (2.31) 163.14 (7.07)
Psychotic Symptoms (Delusions) 65
Pertinence 59.98 (0.89) 60.38 (0.00) 60.38 (0.00) --
Clarity 57.11 (3.30) 57.55 (2.48) 58.60 (1.54) 56.88 (3.54)
Psychotic Symptoms (Hallucinations) 35
Pertinence 30.11 (0.89) 30.71 (0.00) 30.71 (0.00) --
Clarity 29.60 (0.73) 29.55 (1.33) 30.71 (0.00) 30.21 (0.71)
Psychotic Symptoms (Disorganization 
Symptoms) 35
Pertinence 29.46 (1.90) 28.88 (2.40) 30.43 (0.57) --
Clarity 29.26 (1.79) 27.88 (2.86) 29.71 (0.82) 29.21 (2.12)
Psychotic Symptoms (Negative 
Symptoms - Total) 40
Pertinence 34.43 (1.30) 35.29 (0.82) 35.63 (0.00) --
Clarity 32.95 (2.32) 33.60 (2.30) 34.88 (1.50) 35.13 (0.71)
Mood Section 90
Pertinence 83.68 (3.05) 85.11 (0.41) 83.03 (2.87) --
Clarity 80.48 (4.21) 82.27 (2.84) 84.28 (1.15)) 85.28 (0.00)
Substance-Use Section 105
Pertinence 99.44 (1.79) 100.24 (0.00) 98.24 (4.00) --
Clarity 96.84 (5.08) 99.07 (1.60) 98.49 (1.50) 100.24 (0.00)
Social Anxiety Section 40
Pertinence 35.23 (0.89) 34.77 (2.09) 34.88 (1.50) --
Clarity 33.80 (1.91) 34.44 (2.09) 35.38 (0.50) 35.63 (0.00)
Trauma Section 35
Pertinence 30.11 (0.89) 29.86 (2.10) 29.96 (1.50) --
Clarity 29.29 (2.05) 30.36 (0.56) 30.46 (0.50) 30.71 (0.00)
Diagnosis specific questions 315
Pertinence 304.87 (9.49) 306.75 (3.01) 308.08 (2.45) --
Clarity 295.07 (12.34) 296.91 (7.89) 303.83 (3.86) 304.08 (8.49)
Diagnosis-independent ratings 95
Pertinence 88.67 (2.61) 90.26 (0.00) 87.26 (6.00) --
Clarity 84.46 (8.32) 87.93 (4.76) 89.93 (0.58) 88.76 (2.12)
SD=Standard deviation
*Considering the academic background (in terms of psychopathology) in Portugal for social workers, we instructed the two professionals to evaluate the 
interview only regarding clarity.
components of clinical assessment are covered with a sin-
gle instrument (instead of using multiple assessment tools) 
can contribute to lighter assessment (and, therefore, a 
more valid one). Nevertheless, the CIPD does not aim at 
replacing or constituting itself as an alternative to other 
tools developed considering the recovery approach (as-
sessing non-symptom related specific aspects of recovery) 
and a combination with those instruments may be needed 
for an integrative assessment. For instance, although the 
‘empowerment with symptoms’ scales’ provided by CIPD 
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were developed based on ‘empowerment’ definitions con-
gruent with the Recovery Model, they do not intend to 
measure empowerment in a global sense (in terms of life 
directedness, independence of health services, social em-
powerment, and other more general components). Since 
CIPD is an interview for psychotic symptoms (although 
assessed in a way not exclusively focusing on symptom fre-
quency/severity) the main aim of the empowerment scales 
is to understand the way people experience symptoms to 
be in their control, believe in the possibility of improving 
difficulties, have sense of hope and plans for improvement. 
The potential advantage of CIPD is to include a wider as-
sessment of symptoms and relationship with symptoms in 
a tool that also allows for diagnostic purposes.
Recommendations and future directions
Given the semi-structured nature of the CIPD, this inter-
view is designed to be administered by interviewers that: a) 
have basic understanding of psychopathology, mental state 
examination, psychiatric disorders, and in-depth knowl-
edge of psychotic disorders; b) are familiar with assessment 
and diagnostic procedures; c) are able to exercise clinical 
judgment (further questioning for differential diagnosis 
when needed and for decision-making based on direct 
observation of manifest psychopathologic symptoms in 
the context of poor insight). It is recommended that the 
clinician/researcher have some time available after the in-
terview in order to review answers and score the rating 
forms. In spite of the information collected through the 
expert panel, the CIPD’s clinical and research utility should 
be tested in clinical and research settings. The validation of 
the CIPD is already under way  with the following param-
eters:  a) interrater reliability; b) convergent and divergent 
validity of specific sections of the CIPD; c) sensitivity and 
specificity (ability to detect differences in different psy-
chotic diagnostic categories and ability to correctly identify 
the diagnosis given by the patient’s psychiatrist); c) factor 
structure of the quantitative ratings; and d) predictive va-
lidity (measuring change after clinical intervention).
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